Arachidonic acid metabolism in TNS-induced chronic and immunologic enteritis in rats, and the effect of 5-ASA

Inflammation of the rat distal intestine was induced by intradermal sensitization and subsequent multiple intrajejunal challenge with the hapten 2,4,6-trinitrobenzenesulphonic acid (TNBS) via an implanted catheter. The time course of the inflammatory reaction was followed by determination of the enteritis score and measurement of in vitro eicosanoid formation of homogenates of the gut after 0, 1, 2, 4, 7, 14 and 21 days of local daily challenge with 0.08% TNBS. There was a small initial increase of eicosanoid formation, reached at days 1 and 2, followed by a significant increase in metabolism of arachidonic acid on day 21. Although at day 1 a four-fold increase in inflammation score was reached, no further significant changes were observed during the following 3 weeks. The greatest increase in metabolite formation was observed in prostanoids TxB2, PGE2. and PGD2 and the 5-lipoxygenase product LTC4, whereas minor changes were found for LTB4 and other lipoxygenase products such as 12- and 15-HETE. The formation of these metabolites was already inhibited by low-dose 5-aminosalicylic acid (5-ASA), given orally twice daily during the 3 weeks challenge period, while the enteritis score was affected dosedependently.


Introduction
Cytokines and adhesion molecules play an important role in normal immune regulation, 1'2 haematopoieses 3-5 and inflammatory responses. 6 Imbalances in the production of cytokines, particularly those affecting inflammation response, can have profound effects on immunoregulation and may contribute to pathogenesis of numerous diseases. 6'7 High physiological levels of cytokines and enhanced expression and production of soluble adhesion molecules have been implicated in a number of clinical situations. 6 Recently, considerable interest has also been focused on the adhesion molecules, s particularly for their role in pathogenesis during inflammatory processes. Cytokines are known to activate 4'9 a wide variety of killer lineage cells, induce cytokine production and adhesion molecules expression. PTX has been shown 1'11 to modulate neutrophil and monocyte functions. In the present study, to understand the mechanism and immuno-modulatory potential, the effects of PTX on the activation of peripheral blood mononuclear cells (PBMC), killer cells function, production of cytokines, surface receptor expression of cytokines and adhesion molecules was examined.

Materials and methods
Pentoxifylline" Lot 61H0058 was purchased from Sigma (St Louis, MO, USA) and a stock solution *A part of this work was presented at 8th International Congress of Immunology Meeting, Budapest, Hungary, 23 (a) PBMC (1 x 106/ml) q-IL-2 100 U or IL-6 100 U (b) qM (1 x 106 ml) alone or + LPS 10/g/ml (c) PBMC alone or + LPS 10 #g/ml (d) PBMC + LPS + PTX (0-250 ng/well/250 #1) Effects of PTX on yIL-2, IL-6 and LPS induced proliferation of PBMC was measured by [3H]TdR uptake in culture (a) after 72h. Culture (b) containing qM was used in antibody dependent cytotoxicity (ADCC) type killer assays. Fresh PBMC alone or after co-culturing with yIL-2 1000 U/1 x 106 PBMC/ml for 3   Manufacturer's guidelines were followed to measure these cytokines. 4'7 Supernatant from PBMC cultured without LPS and PTX were considered negative controls, whereas supernatant from PBMC plus LPS were considered positive controls. Cytokine surface receptor assay: Using fluorokine kits (British Biotechnology, R & D System, UK) surface receptors for IL-I, IL-2 and TNFwere measured on resting or activated (with LPS) PBMC with or without co-culturing with PTX as described earlier in the methodology. Manufac-turer's guidelines were followed to measure the receptor of the cytokine using fluorescence microscopy (Zeiss, Germany) or FACS (Flow Cytometry). Results were expressed as a percentage of positive cells compared with unactivated PBMC.
Expression of adhesions molecules LFA-1, Macand 1CAM-l: Adhesion molecules (LFA-1, Mac-1 and ICAM-1) on LPS activated PBMC (with or without PTX) were measured by indirect labelling. PBMC were first incubated with anti-LFA-1 (1:20 dilution), anti-Mac-1 (1:25 dilution) or anti-ICAM-1 (1:50 dilution, Bender & Co., Vienna, Austria) monoclonal antibody for 1 h at room temperature. After washing secondary labelling was carried out using goat anti-mouse FITC antibody (1:25 dilution) for 45 min. Negative controls were set up by excluding primary antibody. PBMC was analysed with FACScan (Becton and Dickinson, USA) and fluorescence microscopy (Zeiss, Germany). Results were expressed as percentage of positive cells. Statistical evaluation" The results were expressed as the mean-t-the standard error (S.E.). The difference between mean values was considered significant at p _< 0.05. This was determined with Student's t-test when comparing two sets of means. A two-way analysis of variance was employed for comparing percentage of specific cytotoxicity under two different conditions, inclusive of all effector" target ratios.

Results
Effects of PTX on and cytokine induced activation of PBMC: PBMC activation either with LPS or cytokines, that is IL-2 and IL-6, was down-regulated in a dosedependent manner when PTX was added to the cultures at the initiation of the cultures (Fig. 1) indicating suppressive effect on the pre-effector level. Addition of PTX to unstimulated PBMC had no significant effect on [3H]TdR incorporation.
Once the PBMC had achieved their maximum activations, additions of PTX was somewhat less effective (results not shown). A maximum suppression was achieved at 250 ng/well/250/1 of PTX concentration (p < 0.002 for IL-2; p < 0.023 for IL-6 and p < 0.005 for LPS). Effects of PTX on the dM mediated cytotoxicity: The activated macrophages mediated cytotoxicity was down-regulated in a dose-dependent manner (Fig. 2)  Effects of PTX on NK and LAK cell function: Addition of PTX (10-250 ng/well/250/.tl) to both NK and LAK cell assays at the initiation of cultures resulted in a dose-dependent suppression (Fig. 3). A highly significant suppression p < 0.001 was noted for both NK and LAK cells at 250 ng PTX/well or MAC-l, ICAM-1 revealed a dose-dependent suppression of LFA-1 and MAC-1 adhesion molecules whereas ICAM-1 expression was modulated only at higher concentrations of PTX (>_100ng/ 10 6 PBMC/well) (Fig. 6).

Discussion
Polymorphonuclear neutrophils (PMN) participate significantly during certain pathological states to induce a variety of cellular injuries. 18 Activation of PMN may lead to free oxygen radical production, enhance cytotoxicity via proteolytic enzymes and lead to increased adhesion to endothelial-cell lining. 19  cytokines. 4's PTX mediated modulation of neutrophil functions has been reported in previous studies. 11 '22'23 The authors 17 and others 24'2s recently showed that endotoxin induced cytokines i.e. IL-I TNFand IL-6 are implicated in the pathophysiology of acute heat stroke patients. Imbalance in cytokine or their soluble receptor production, killer cell activation and adhesion molecule expression has also been implicated in a number of diseases. 26 The aim of the present study was to analyse to what degree PTX interferes with various immune cell functions that are thought to play roles in a variety of normal and abnormal inflammatory states. The results of this study clearly demonstrate that PTX can block activation and subsequent generation of killer lineage cells in a dose-dependent manner. LPS induced nonspecific activation of PBMC or cytokine mediated cytotoxicity, as measured either by using [3H]TdR uptake or cytotoxicity assay, was significantly suppressed, when PTX was added at the initiation of PBMC proliferation or killer cell assay. The significant suppression in mixed lymphocyte culture (MLR) and subsequent generation of allo-specific cytotoxic T-lymphocyte (CTL) killer cells (data not shown) was only achieved at a high concentration of PTX (_> 20 pg/ml), when PTX was introduced into the culture at 0 h. Once the allo-specific CTL cytotoxic killer cells were generated, addition of PTX even at 10-20 pg/ml during the CTL assay was less effective. An early report 28 on a phase I--II human trial using PTX for the prevention of transplant related toxicity following bone marrow transplant (BMT), showed significant suppression in the level of circulating TNFand was associated with the reduction in morbidity and mortality in patients undergoing BMT. LPS induced cytokine (IL-1, IL-2, IL-6, TNF-0 and IFN-y) and surface receptor expression of IL-, IL-2 and TNFwere significantly affected only when PTX was added at the beginning of the culture, indicating that once the maximum activation of PBMC had been achieved, PTX was no longer able to suppress the production of these cytokines. However, a recent :tudy 29 showing a differential effect of PTX on TNFand IL-6 production in vivo in response to OKT3 monoclonal antibody in transplant patients clearly demonstrated a different mechanism of PTX action, depending on the cellular origin of these cytokines and the availability of accessory cells which can modulate the antigen presentation during induction of cytokine production. In the present study the effect of PTX on LPS stimulated PBMC, not on the pure macrophages population was measured. The amount of cytokines produced is the total amount secreted by T-lymphocytes and macrophages together, so a selective effect of PTX on either population of cells producing cytokines cannot be differentiated.
The expression of adhesion molecules, LFA-1, Mac-1 and ICAM-1, on PBMC was significantly affected by PTX at higher concentrations only.
Modulation of various adhesion molecules on human endothelial cells activated with various cytokines was less affected using similar concentrations of PTX (R. S. Parhar and S. Al-Sedairy, manuscript in preparation) indicating that regulation of endothelial cell surface adhesion molecule expression could be different to that of PBMC.
IL-1, IL-2, TNF-, IL-6 and IFN-2 are implicated in the pathogenesis of several clinical settings including arthritis, septic shock, hyperthermia and organ transplantation. A high level of soluble ICAM-1 adhesion receptor has been reported in malignant melanoma patients. 3 The ability of PTX to suppress surface receptor expression of adhesion molecules merits further study to evaluate its role in malignant diseases. PTX has recently been shown to inhibit mRNA expression of TNF-29 in PBMC and TNFand IL-1/ in HL-60 leukaemia cells. 31 Though the precise inhibitory mechanism of PTX at the molecular level is still elusive, its ability to down-regulate the cytokine surface receptor expression and cytokine production appears to be the key mechanism in down-regulating the activation of leukocytes macrophages, NK and LAK cell mediated cytotoxicity. Since the surface receptor expression of IL-I, IL-2, TNF-, IFNand adhesion molecules on killer lineage cells is related to cell activation and cytotoxic state, it is speculated that the mechanism of the PTX effect may be explained by its ability to down-regulate and suppress the mRNA of inflammatory cytokines which subsequently induce adhesion molecule expression and their production. The ability of PTX to down-regulate, modulate and suppress killer lineage cell function, cytokine and adhesion molecule expression and production, respectively, warrant studies in various clinical settings to evaluate its therapeutic benefits.